
How High Can SharkNinja Stock Go?
If you know popular consumer appliance brands Shark and Ninja,…
Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
---|---|---|---|---|---|
CLDI
Calidi Biotherapeutics
|
-- | -$0.11 | -- | -99.21% | $6.25 |
IMRX
Immuneering
|
-- | -$0.42 | -- | -19.68% | $11.42 |
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
NNVC
Nanoviricides
|
-- | -$0.20 | -- | -26.67% | -- |
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
TOVX
Theriva Biologics
|
-- | -$0.47 | -- | -95.63% | $7.00 |
Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
---|---|---|---|---|---|---|---|
CLDI
Calidi Biotherapeutics
|
$0.58 | $6.25 | $18.4M | -- | $0.00 | 0% | -- |
IMRX
Immuneering
|
$4.17 | $11.42 | $150.1M | -- | $0.00 | 0% | 414.71x |
NBY
NovaBay Pharmaceuticals
|
$0.69 | $0.85 | $4M | -- | $0.00 | 0% | 0.16x |
NNVC
Nanoviricides
|
$1.60 | -- | $25.7M | -- | $0.00 | 0% | -- |
OGEN
Oragenics
|
$1.41 | $1.00 | $1M | -- | $0.00 | 0% | 0.45x |
TOVX
Theriva Biologics
|
$0.50 | $7.00 | $4.1M | -- | $0.00 | 0% | 0.33x |
Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
---|---|---|---|---|
CLDI
Calidi Biotherapeutics
|
-- | 2.861 | -- | -- |
IMRX
Immuneering
|
-- | 6.440 | -- | -- |
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.044 | 1.51% | 0.75x |
NNVC
Nanoviricides
|
-- | -0.318 | -- | -- |
OGEN
Oragenics
|
-- | 0.068 | -- | -- |
TOVX
Theriva Biologics
|
-- | -3.388 | -- | -- |
Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
---|---|---|---|---|---|---|
CLDI
Calidi Biotherapeutics
|
-- | -$5M | -- | -- | -- | -$7.1M |
IMRX
Immuneering
|
-- | -$15.5M | -- | -- | -- | -$14.1M |
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$2.7M | -334.47% | -461.38% | -44% | -$1.3M |
NNVC
Nanoviricides
|
-- | -$2.2M | -- | -- | -- | -$2M |
OGEN
Oragenics
|
-- | -$2M | -- | -- | -- | -$2.1M |
TOVX
Theriva Biologics
|
-- | -$4.4M | -- | -- | -- | -$4.8M |
Immuneering has a net margin of -- compared to Calidi Biotherapeutics's net margin of --. Calidi Biotherapeutics's return on equity of -- beat Immuneering's return on equity of --.
Company | Gross Margin | Earnings Per Share | Invested Capital |
---|---|---|---|
CLDI
Calidi Biotherapeutics
|
-- | -$0.18 | -- |
IMRX
Immuneering
|
-- | -$0.42 | -- |
Calidi Biotherapeutics has a consensus price target of $6.25, signalling upside risk potential of 1627.12%. On the other hand Immuneering has an analysts' consensus of $11.42 which suggests that it could grow by 173.78%. Given that Calidi Biotherapeutics has higher upside potential than Immuneering, analysts believe Calidi Biotherapeutics is more attractive than Immuneering.
Company | Buy Ratings | Hold Ratings | Sell Ratings |
---|---|---|---|
CLDI
Calidi Biotherapeutics
|
2 | 0 | 0 |
IMRX
Immuneering
|
3 | 1 | 0 |
Calidi Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Immuneering has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
Calidi Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immuneering offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Calidi Biotherapeutics pays -- of its earnings as a dividend. Immuneering pays out -- of its earnings as a dividend.
Calidi Biotherapeutics quarterly revenues are --, which are smaller than Immuneering quarterly revenues of --. Calidi Biotherapeutics's net income of -$5M is higher than Immuneering's net income of -$15M. Notably, Calidi Biotherapeutics's price-to-earnings ratio is -- while Immuneering's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Calidi Biotherapeutics is -- versus 414.71x for Immuneering. Usually stocks with elevated PS ratios are considered overvalued.
Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
---|---|---|---|---|
CLDI
Calidi Biotherapeutics
|
-- | -- | -- | -$5M |
IMRX
Immuneering
|
414.71x | -- | -- | -$15M |
NovaBay Pharmaceuticals has a net margin of -- compared to Calidi Biotherapeutics's net margin of -49.65%. Calidi Biotherapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company | Gross Margin | Earnings Per Share | Invested Capital |
---|---|---|---|
CLDI
Calidi Biotherapeutics
|
-- | -$0.18 | -- |
NBY
NovaBay Pharmaceuticals
|
65.26% | $1.42 | $1.1M |
Calidi Biotherapeutics has a consensus price target of $6.25, signalling upside risk potential of 1627.12%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 23.19%. Given that Calidi Biotherapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Calidi Biotherapeutics is more attractive than NovaBay Pharmaceuticals.
Company | Buy Ratings | Hold Ratings | Sell Ratings |
---|---|---|---|
CLDI
Calidi Biotherapeutics
|
2 | 0 | 0 |
NBY
NovaBay Pharmaceuticals
|
1 | 0 | 0 |
Calidi Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.
Calidi Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Calidi Biotherapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
Calidi Biotherapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Calidi Biotherapeutics's net income of -$5M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Calidi Biotherapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Calidi Biotherapeutics is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
---|---|---|---|---|
CLDI
Calidi Biotherapeutics
|
-- | -- | -- | -$5M |
NBY
NovaBay Pharmaceuticals
|
0.16x | -- | $2.4M | $7.7M |
Nanoviricides has a net margin of -- compared to Calidi Biotherapeutics's net margin of --. Calidi Biotherapeutics's return on equity of -- beat Nanoviricides's return on equity of --.
Company | Gross Margin | Earnings Per Share | Invested Capital |
---|---|---|---|
CLDI
Calidi Biotherapeutics
|
-- | -$0.18 | -- |
NNVC
Nanoviricides
|
-- | -$0.14 | -- |
Calidi Biotherapeutics has a consensus price target of $6.25, signalling upside risk potential of 1627.12%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 306.25%. Given that Calidi Biotherapeutics has higher upside potential than Nanoviricides, analysts believe Calidi Biotherapeutics is more attractive than Nanoviricides.
Company | Buy Ratings | Hold Ratings | Sell Ratings |
---|---|---|---|
CLDI
Calidi Biotherapeutics
|
2 | 0 | 0 |
NNVC
Nanoviricides
|
0 | 0 | 0 |
Calidi Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.802%.
Calidi Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Calidi Biotherapeutics pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.
Calidi Biotherapeutics quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. Calidi Biotherapeutics's net income of -$5M is lower than Nanoviricides's net income of -$2.2M. Notably, Calidi Biotherapeutics's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Calidi Biotherapeutics is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.
Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
---|---|---|---|---|
CLDI
Calidi Biotherapeutics
|
-- | -- | -- | -$5M |
NNVC
Nanoviricides
|
-- | -- | -- | -$2.2M |
Oragenics has a net margin of -- compared to Calidi Biotherapeutics's net margin of --. Calidi Biotherapeutics's return on equity of -- beat Oragenics's return on equity of --.
Company | Gross Margin | Earnings Per Share | Invested Capital |
---|---|---|---|
CLDI
Calidi Biotherapeutics
|
-- | -$0.18 | -- |
OGEN
Oragenics
|
-- | -$3.60 | -- |
Calidi Biotherapeutics has a consensus price target of $6.25, signalling upside risk potential of 1627.12%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2027.87%. Given that Oragenics has higher upside potential than Calidi Biotherapeutics, analysts believe Oragenics is more attractive than Calidi Biotherapeutics.
Company | Buy Ratings | Hold Ratings | Sell Ratings |
---|---|---|---|
CLDI
Calidi Biotherapeutics
|
2 | 0 | 0 |
OGEN
Oragenics
|
0 | 1 | 0 |
Calidi Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.
Calidi Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Calidi Biotherapeutics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
Calidi Biotherapeutics quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Calidi Biotherapeutics's net income of -$5M is lower than Oragenics's net income of -$2.2M. Notably, Calidi Biotherapeutics's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Calidi Biotherapeutics is -- versus 0.45x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
---|---|---|---|---|
CLDI
Calidi Biotherapeutics
|
-- | -- | -- | -$5M |
OGEN
Oragenics
|
0.45x | -- | -- | -$2.2M |
Theriva Biologics has a net margin of -- compared to Calidi Biotherapeutics's net margin of --. Calidi Biotherapeutics's return on equity of -- beat Theriva Biologics's return on equity of --.
Company | Gross Margin | Earnings Per Share | Invested Capital |
---|---|---|---|
CLDI
Calidi Biotherapeutics
|
-- | -$0.18 | -- |
TOVX
Theriva Biologics
|
-- | -$1.55 | -- |
Calidi Biotherapeutics has a consensus price target of $6.25, signalling upside risk potential of 1627.12%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1308.45%. Given that Calidi Biotherapeutics has higher upside potential than Theriva Biologics, analysts believe Calidi Biotherapeutics is more attractive than Theriva Biologics.
Company | Buy Ratings | Hold Ratings | Sell Ratings |
---|---|---|---|
CLDI
Calidi Biotherapeutics
|
2 | 0 | 0 |
TOVX
Theriva Biologics
|
1 | 1 | 0 |
Calidi Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.
Calidi Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Calidi Biotherapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
Calidi Biotherapeutics quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Calidi Biotherapeutics's net income of -$5M is lower than Theriva Biologics's net income of -$4.3M. Notably, Calidi Biotherapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Calidi Biotherapeutics is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
---|---|---|---|---|
CLDI
Calidi Biotherapeutics
|
-- | -- | -- | -$5M |
TOVX
Theriva Biologics
|
0.33x | -- | -- | -$4.3M |
Signup to receive the latest stock alerts
If you know popular consumer appliance brands Shark and Ninja,…
Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…
If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…
Market Cap: $4T
P/E Ratio: 56x
Market Cap: $3.8T
P/E Ratio: 43x
Market Cap: $3.1T
P/E Ratio: 34x
Veritex Holdings [VBTX] is down 3.26% over the past day.
Monopar Therapeutics [MNPR] is down 8.6% over the past day.
Nebius Group NV [NBIS] is up 2.98% over the past day.